Two antibodies dominate a scleroderma panel, anti-centromere and anti-Scl-70, and they are rarely positive in the same person. Neither one confirms nor excludes a condition by itself. Both are interpreted next to symptoms, examination findings and other laboratory results, and the next step after either is a clinical review rather than a conclusion.
An anti-centromere antibody is an autoantibody that binds proteins at the centromere, the constricted region where a chromosome's two arms meet and where the cell's spindle attaches during division. The immune system is not supposed to produce antibodies against its own chromosomal machinery, so the presence of these antibodies says something about immune behaviour rather than anything about a person's chromosomes.
Most of these antibodies recognise one of three centromere proteins, CENP-A, CENP-B and CENP-C. CENP-B is the target recognised most often, which is why many laboratories report a specific CENP-B result instead of a generic one. The antibodies are almost always of the IgG class, so a report that reads centromere antibody IgG is describing the usual form rather than a separate or unusual variant.
Most people meet this test only because something else turned up first. A screening antinuclear antibody test on HEp-2 cells produces a staining pattern under the microscope, and a discrete speckled pattern, with speckles visible on dividing cells as well as resting ones, is the classic appearance of centromere reactivity. The guide to a positive ana test covers what that screening step does and does not say on its own. The centromere test is one of several follow-ups used to put a name to the pattern, rather than a test most people are offered from scratch.
It is worth separating two ideas at the start. The antibody is a marker of a particular immune pattern. It is not a measure of how someone feels, how fast anything is changing, or whether any organ is currently involved.
It matters because it turns a vague positive screening test into a specific immune signature, and because that signature tells a clinician what to look for and what to keep watching. A positive antinuclear antibody test on its own is common and non-specific, and it appears in plenty of people who never develop an autoimmune condition. A defined antibody narrows the field to a smaller group of connective tissue conditions, chiefly the limited cutaneous form of systemic sclerosis, the condition most people know as scleroderma and whose older label CREST stood for calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly and telangiectasia.
Research suggests that systemic sclerosis develops through three interacting processes, immune activation, injury to small blood vessels and excessive deposition of fibrous tissue 1. Autoantibodies sit inside the first of those processes. The antibody itself is not thought to be the direct cause of thickened skin, but the pattern of antibodies a person carries tends to travel with a particular clinical picture, and that is what makes the result useful.
The practical value is in planning. The antibody profile helps a clinician decide which organs deserve a baseline assessment, how often to repeat that assessment, and how closely to follow a person whose only current complaint might be fingers that turn white and then blue in the cold. What the result does not do is state that a condition is present, grade how active it is, or predict how it will behave in one individual.
They differ in the protein they bind, in the skin pattern they usually accompany, and in which organs clinicians watch most closely afterwards. Anti-Scl-70, often written as anti scl-70 antibodies, is directed against the enzyme DNA topoisomerase I, and is associated with the diffuse cutaneous form of systemic sclerosis and with lung fibrosis 2. Anti-centromere positivity, by contrast, is associated with the limited cutaneous subset. The two are rarely positive in the same person, which is exactly why a scleroderma panel usually reports both.
| Feature | Anti-centromere | Anti-Scl-70 (anti-topoisomerase I) |
|---|---|---|
| Protein targeted | Centromere proteins, chiefly CENP-A, CENP-B and CENP-C | The enzyme DNA topoisomerase I |
| Typical HEp-2 appearance | Discrete speckled, with speckles on dividing cells | Fine speckled, often with nucleolar staining |
| Skin pattern usually accompanying it | Limited cutaneous | Diffuse cutaneous |
| Common early feature | Raynaud's phenomenon, often present for years | Raynaud's with more rapid skin change |
| Organ areas clinicians tend to follow | Gut motility, finger ulcers, calcinosis, pressure in the lung arteries | Lung fibrosis, heart, kidney |
| Found together | Rarely positive in the same person | Rarely positive in the same person |
A note on the words limited and diffuse, because they mislead people. They describe how much skin is involved, not how much the condition matters. Limited cutaneous disease can still involve internal organs, and people with it are followed for swallowing and reflux problems, digital ulcers, calcium deposits in the skin and raised pressure in the lung arteries. Diffuse disease tends to move faster in the skin and brings a different set of surveillance priorities. Neither antibody predicts an individual course, and neither replaces an examination.
Occasionally a report shows neither antibody, or shows a different one entirely. That is covered further down, because a negative panel is its own kind of result.
A positive result means the laboratory detected antibodies against centromere proteins in that sample, and nothing beyond that. What the finding may reflect depends completely on the rest of the picture.
In a person with long-standing Raynaud's phenomenon, tightening of the skin over the fingers, small dilated vessels on the face or hands, or persistent reflux, it supports a clinician's suspicion of limited cutaneous systemic sclerosis and usually leads to a structured assessment. In a person with no symptoms whatsoever, found incidentally during an autoimmune workup for something else, it may be an isolated laboratory finding that calls for periodic review rather than action.
These antibodies also appear in some people with primary biliary cholangitis, an autoimmune liver condition, and in a minority of people with other connective tissue conditions. They can also appear in people whose only feature is Raynaud's phenomenon, and that group is typically followed over time rather than labelled early.
So the honest reading is three steps. The observation is that a specific autoantibody is present. The possible meaning is an immune pattern that commonly accompanies the limited cutaneous form of systemic sclerosis, or less often another autoimmune condition. The next step is a conversation with a clinician, usually a rheumatologist, who can examine the nailfold capillaries, take a full history and decide what baseline assessment makes sense. Classification of systemic sclerosis draws on a combination of skin changes, nailfold capillary abnormalities, finger ulcers, telangiectasia, lung findings and antibody status, and no single item is sufficient on its own.
Raynaud's phenomenon comes up because it is usually the earliest visible sign of the small vessel changes that run through this group of conditions. In Raynaud's, fingers or toes change colour in response to cold or stress, classically turning pale, then dusky, then red as blood flow returns, often with numbness or pain.
Raynaud's on its own is extremely common and most often primary, meaning there is no underlying connective tissue condition. What separates primary from secondary Raynaud's is the company it keeps, and this is where antibody testing earns its place. A positive antinuclear antibody test, a defined autoantibody such as anti-centromere, abnormal nailfold capillaries under magnification, digital ulcers or pitting scars all push a clinician toward secondary Raynaud's and a longer look.
Research suggests that injury to small blood vessels is one of the core processes in systemic sclerosis, alongside immune activation and fibrosis 1, which is why the fingers often signal first. Nailfold capillaroscopy, a painless look at the capillaries at the base of the nail under magnification, is a routine part of that assessment and tells a clinician things no blood test can.
The practical point for a reader with cold, colour-changing fingers and a positive antibody is simple. It is a reason to be assessed properly, not a reason to assume the worst. Many people in this situation are monitored for years without further developments.
A high CENP-B value means strong antibody binding in that particular assay, not advanced or severe disease. A report that reads centromere b antibody high is describing reactivity against the CENP-B protein in units specific to the method that laboratory uses, and those units are not comparable between laboratories or between platforms.
Antibody strength and clinical severity are different things. A person with a modest positive can have more organ involvement than a person with a very high value, and tracking the number over months rarely adds useful information. For that reason, clinicians generally care whether the antibody is present, then monitor the person rather than the number.
There is one caveat worth knowing. A weak or borderline positive deserves more caution than a strong one, because results near an assay's cut-off are the least reproducible. A clinician may repeat a borderline value at the same laboratory, or ask for a different method, before reading much into it.
A negative result makes limited cutaneous systemic sclerosis less likely, but it does not exclude it, and it says nothing about other autoimmune conditions. Several autoantibodies occur in systemic sclerosis beyond the two that dominate most panels, including anti-RNA polymerase III, anti-U3 RNP, anti-Th/To and anti-PM/Scl. A panel that reports only centromere and Scl-70 will not detect the others, so which tests were ordered matters as much as what they showed.
There is also a group of people who fit the clinical picture with no detectable antibody at all. Symptoms and examination findings outrank a negative antibody result every time. Fingers that change colour in the cold, skin that is tightening, swallowing that has changed or new breathlessness all deserve attention regardless of what a panel shows.
A negative result can also be the right result. For a person whose antinuclear antibody test was positive at a low level with no symptoms, negative follow-up testing is reassuring context, and the usual outcome is observation rather than further testing.
It is an ordinary blood draw with no fasting or special preparation, and the result is reported either as a pattern, as a yes or no, or as a number against a cut-off. Laboratories commonly screen with indirect immunofluorescence on HEp-2 cells, where centromere reactivity produces the discrete speckled pattern described earlier, then confirm with a solid phase method such as an ELISA, a line immunoassay or a multiplex bead assay that measures reactivity to CENP-B specifically.
| How the result is reported | Typical units or format | Typical lab reference range |
|---|---|---|
| Qualitative | Negative, equivocal or positive | Negative |
| Semi-quantitative immunoassay | AU/mL, U/mL or an index value | Below the assay's stated cut-off |
| Immunofluorescence titre | A dilution, for example 1:80, 1:160 or 1:320 | Below the laboratory's reporting threshold |
| Pattern description | Discrete speckled, including dividing cells | Not applicable |
These are typical laboratory reference ranges and reporting formats. Ranges and cut-offs vary by laboratory, assay, age and sex, so read any result against the range printed on your own report rather than against a figure found online.
Because platforms differ, a sample that reads positive on one method can read negative on another when the value sits close to the cut-off. Repeating a borderline result at the same laboratory is more informative than comparing numbers between providers. Results usually come back within a few days, and the sample is stable enough that most laboratories batch these tests rather than running them immediately.
Four things shape what the report says: the method used, where the cut-off sits, when the sample was taken, and what else is going on immunologically.
Method comes first. Solid phase assays measure binding to a purified protein, usually CENP-B, while immunofluorescence reads a whole-cell pattern. A sample with strong reactivity to CENP-A or CENP-C but weaker reactivity to CENP-B can look convincing by pattern and modest by immunoassay. Neither reading is wrong, they are measuring slightly different things.
Cut-offs come second. Each laboratory validates its own threshold, so an identical sample can be reported as equivocal in one place and positive in another. This is the single most common reason a result appears to change after switching providers.
Timing comes third. Autoantibodies can be detectable well before a clinical picture becomes obvious, which is why a positive result in a person whose only feature is Raynaud's phenomenon prompts follow-up rather than reassurance. The reverse also occurs, with early clinical features and no detectable antibody yet.
Background immune noise comes fourth. Low-level antinuclear antibody positivity becomes more common with age and is found in plenty of people with no autoimmune condition, so a weak positive in someone with no symptoms carries less weight than a strong positive in someone with matching findings. Some medicines can prompt the immune system to produce autoantibodies, which is one reason a clinician reviews a full medicine list when interpreting an unexpected positive.
Day-to-day factors are a small influence here. Unlike many metabolic markers, antibody results are not meaningfully changed by fasting status, time of day or a recent workout.
ESR is a non-specific marker of inflammation, and it answers a different question from an antibody test. It cannot identify which condition is present, but it gives a rough sense of whether an inflammatory process is active, which is why it often sits on the same request form. FitScript's optimal range for ESR is 0 to 10 mm/hr in men and 0 to 15 mm/hr in women, against typical laboratory reference ranges of 0 to 22 mm/hr and 0 to 29 mm/hr respectively. Optimal ranges are optimization targets, not diagnostic cut-offs. For what the marker measures, how it is run and how to read a specific value, the dedicated guide to ESR covers it in full.
The useful companions are the ones that either broaden the antibody search or check the organs most often involved. A clinician decides which of these apply, and the list below is context rather than a shopping list.
The antinuclear antibody test with its pattern is the natural starting point, because the pattern itself often predicts which specific antibody will be found. A wider extractable nuclear antigen panel adds the other named antibodies, including anti-RNP, which points toward a different clinical picture again and is covered in the guide to the anti rnp test.
Anti-Ro52, also known as TRIM21, is frequently added. Anti-Ro52 positivity is associated with interstitial lung disease in people with systemic sclerosis 3, which is why its presence tends to sharpen attention on the chest.
Autoimmune conditions also cluster within the same person, so thyroid antibodies are commonly checked alongside connective tissue markers. The practical background on that marker sits in the guide on how to lower tpo antibodies.
Beyond antibodies, a clinician may want a full blood count, kidney function with a urine test, liver markers given the overlap with primary biliary cholangitis, and inflammation markers. Pulmonary function testing and imaging are not blood tests, but they answer the questions a blood panel cannot. FitScript's membership covers 150+ biomarkers tested per year with interpretation by Atlas, its AI health advisor, though specialist autoantibody follow-up and any treatment decisions belong to a licensed provider.
Anti-Scl-70 is the result that most often turns attention to the lungs, and anti-centromere usually turns it toward the lung blood vessels instead. Interstitial lung disease is one of the most common serious organ manifestations of systemic sclerosis and a leading cause of death in the condition 4. That is why screening is taken seriously even when breathing feels normal.
Research suggests that anti-topoisomerase I positivity and the diffuse cutaneous subtype are among the factors associated with interstitial lung disease in systemic sclerosis 5. The same antibody, under its older name, is associated with pulmonary fibrosis in reviews of its clinical significance 2.
Expert consensus algorithms for identifying interstitial lung disease in systemic sclerosis describe the use of high-resolution CT of the chest together with pulmonary function testing 6. In practice this means a baseline assessment near the time of diagnosis and repeat testing at intervals a clinician sets, because early changes are often silent and lung function can drift before symptoms appear.
For people with the limited cutaneous pattern more often seen with anti-centromere antibodies, the lung concern is usually different in kind. Clinicians tend to follow pressure in the lung arteries over time, which is assessed with echocardiography rather than a blood test, alongside the same lung function measurements. Either way, new or worsening breathlessness on exertion, a persistent dry cough or reduced exercise tolerance are worth discussing with a clinician promptly rather than waiting for a scheduled review.
What typically follows is a referral and a baseline assessment, not a prescription. A rheumatologist takes a detailed history covering Raynaud's phenomenon, skin changes, reflux and swallowing, joint symptoms, breathlessness and fatigue, then examines the skin and the nailfold capillaries.
From there, a baseline usually includes lung function testing and chest imaging, an echocardiogram to assess pressure in the lung arteries, and bloodwork covering kidney function, blood counts and inflammation. Gut symptoms may prompt their own assessment. The point of a baseline is comparison. A single lung function result tells a clinician far less than the same test repeated a year later.
Monitoring intervals depend on the antibody profile, the clinical findings and how long symptoms have been present. Some people are reviewed annually with no change for many years. Others need closer follow-up from the start. Treatment decisions belong to a licensed provider who has examined the person and reviewed the full set of results.
One thing worth resisting is the urge to repeat the antibody test for reassurance. It rarely answers the question people want answered, which is how things are going. Organ measurements answer that question. Antibody status mostly does not.
In most people it stays put. Once a specific autoantibody such as anti-centromere or anti-Scl-70 is established, it generally remains detectable, and the value drifts within a range that reflects assay variation more than anything clinical.
That has two consequences. First, repeating the same antibody test is seldom informative once the result is clear, and a rising number is not a reason to assume anything is worsening. Second, an apparent change from positive to negative, or the reverse, is most often explained by a different laboratory, a different method or a value that was always near the cut-off.
There are situations where retesting makes sense, and a clinician is the right person to judge them. Examples include an early borderline result, a clinical picture that has clearly changed in a way the original panel did not explain, or a case where only a narrow panel was run the first time and a broader antibody search is now warranted.
Any positive autoantibody result is worth reviewing with a clinician, and some symptoms are worth raising promptly rather than at the next scheduled appointment.
The prompt list includes new or worsening breathlessness on exertion, a persistent dry cough, chest tightness or a clear drop in exercise tolerance. It also includes ulcers or dark areas at the fingertips, rapidly tightening skin, difficulty swallowing or food sticking, significant unintended weight loss, and a new severe headache with unusually high blood pressure readings. None of these confirms anything on its own, and each is a reason to be seen rather than to search online.
For a result with no symptoms attached, the conversation is calmer but still worth having. Bring the actual report, including the method used and the laboratory's cut-off, along with any previous antinuclear antibody results. Note how long any cold-related colour change in the fingers has been happening, because duration genuinely matters to the assessment.
This article is educational and is not medical advice. Discuss your own results, and any next step or treatment, with a clinician or licensed provider who can see the whole picture.
It means the laboratory detected antibodies against centromere proteins in your sample. On its own that is a finding, not a diagnosis, and it has to be read next to your symptoms, your examination and your other results. The usual next step is a review with a clinician, often a rheumatologist, who decides what baseline assessment makes sense.
Yes, and it happens reasonably often when the test is run as part of a broader autoimmune workup. In that situation a clinician typically documents a baseline and reviews you periodically rather than acting immediately. Report any new cold-related colour change in the fingers, skin tightening, reflux or breathlessness between reviews.
They bind different proteins and usually accompany different patterns of disease. Anti-centromere goes with the limited cutaneous form of systemic sclerosis, while anti-Scl-70 goes with the diffuse cutaneous form and draws more attention to the lungs. The two are rarely positive in the same person, which is why both appear on the same panel.
No. These autoantibodies are almost always of the IgG class, so the label simply describes the usual form that laboratories measure. It is a description of the method and the antibody class, not a separate or more serious result.
No. A high value reflects strong binding in that specific assay, in units set by that laboratory, and it does not grade severity. Clinicians focus on whether the antibody is present and then monitor the organs over time rather than following the number.
No preparation is needed. It is a standard blood draw, and the result is not meaningfully changed by fasting, time of day or recent exercise. If other tests are being drawn at the same time, follow the instructions for those.
Usually not for the same antibody, because antibody status tends to stay stable once it is established. Repeat testing makes more sense when an early result was borderline, when only a narrow panel was run, or when the clinical picture has clearly changed. Your clinician decides whether a repeat adds anything.